|
2025
|
Invention
|
Morpholine-3-carboxamide derivatives as prostaglandin e2 receptor 4 (ep4) agonists for the treatm... |
|
2024
|
Invention
|
Cgrp antagonist compounds.
The disclosures herein relate to novel compounds of Formula (1a): and... |
|
|
Invention
|
Pyrazole derivatives as h4 antagonist compounds.
The disclosures herein relate to novel compound... |
|
|
Invention
|
Crystalline form of an ep4 antagonist. This invention relates to a crystalline form of the compou... |
|
|
Invention
|
Antibodies.
The invention relates to antibodies or antigen-binding fragments thereof which speci... |
|
2023
|
Invention
|
Mutant g-protein coupled receptors and methods for selecting them.
The invention relates to muta... |
|
|
Invention
|
Anti-par2 antibodies.
The present disclosure provides antibodies and antigen-binding fragments c... |
|
|
Invention
|
4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators. The disclosures herein relate to novel ... |
|
2022
|
Invention
|
Gpr52 modulator compounds.
The disclosures herein relate to novel compounds of Formula (1a) or (... |
|
|
Invention
|
Gpr35 agonist compounds.
The disclosures herein relate to novel compounds of formula (1):
The ... |
|
|
Invention
|
Sars-cov-2 mpro inhibitor compounds.
The invention described herein relates to compounds of Form... |
|
|
Invention
|
Pharmaceutical composition for the treatment of alzheimer's disease or dementia.
This invention ... |
|
|
Invention
|
Muscarinic agonists. 4 receptor mediated diseases. Also provided are pharmaceutical compositions ... |
|
2021
|
Invention
|
Sars-cov-2 mpro inhibitor compounds.
The disclosures herein relate to compounds of Formula (1′):... |
|
|
Invention
|
4 receptor. 6 are as defined herein.
|
|
|
Invention
|
H4 antagonist compounds.
The disclosures herein relate to novel compounds of formula (1):
The ... |
|
|
Invention
|
Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators. The disclosu... |
|
|
Invention
|
Linear apelin receptor agonists.
The disclosures herein relate to novel compounds of formula (1)... |
|
|
Invention
|
Cyclic apelin receptor agonists.
The disclosures herein relate to novel compounds of f... |
|
|
Invention
|
Gpr52 modulator compounds.
The disclosures herein relate to novel compounds of Formula (1): or a... |
|
|
Invention
|
Glp-1 receptor antagonists.
The disclosures herein relate to novel internally cyclic peptide com... |
|
|
Invention
|
Muscarinic receptor agonists. 1 receptor mediated diseases. Also provided are pharmaceutical comp... |
|
|
Invention
|
Substituted cyclohexanes as muscarinic m1 receptor and/or m4 receptor agonists. 4 receptor mediat... |
|
|
Invention
|
1,2,4-triazine-4-amine derivatives. 2a receptor. A process for the preparation of the compound, p... |
|
|
Invention
|
H4 antagonist compounds.
The disclosure herein relates to azetidinylpyrimidin-2-amine derivative... |
|
|
Invention
|
Muscarinic m1 receptor agonists. 6 are as defined herein.
|
|
|
Invention
|
5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer.
De... |
|
|
Invention
|
Triazolone compounds.
Described herein are triazalone compounds of Formula (I): and pharmaceutic... |
|
|
Invention
|
Oral glp receptor agonists.
The disclosures herein relate to novel compounds of formula (1a) or ... |
|
|
Invention
|
Glp receptor agonists.
The disclosures herein relate to novel compounds of formula (1): and salt... |
|
|
Invention
|
Gpr52 modulator compounds.
The disclosures herein relate to novel compounds of Formula (1); and ... |
|
2020
|
Invention
|
Cgrp receptor antagonists. The disclosures herein relate to novel compounds of formula
4 are as ... |
|
|
Invention
|
Methods for screening for binding partners of g-protein coupled receptors.
A method of producing... |
|
|
Invention
|
Gpr52 modulator compounds.
The disclosures herein relate to novel compounds of Formula (1): (1) ... |
|
|
Invention
|
Pharmaceutical compounds. 4 receptors. Also provided are pharmaceutical compositions containing t... |
|
|
Invention
|
Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor. 4 are as defined herein.
|
|
|
Invention
|
Cgrp antagonist compounds. 3 are defined herein, and their use in treating, preventing, ameliorat... |
|
|
Invention
|
Cgrp antagonist compounds. 2 are defined herein, and their use in treating, preventing, ameliorat... |
|
|
Invention
|
Mutant g-protein coupled receptors and methods for selecting them. The invention relates to mutan... |
|
|
Invention
|
Oxexin 1 receptor antagonists. 5 are defined herein, and their use in treating, preventing, ameli... |
|
2019
|
Invention
|
Orexin 1 receptor antagonists. 4 are defined herein, and their use in treating, preventing, ameli... |
|
|
Invention
|
4 receptor agonists. 2 are defined herein.
|
|
|
Invention
|
Pyrazole derivatives as h4 antagonist compounds. Novel compounds of formula (1):
2 are defined h... |
|
|
Invention
|
Cyclohexapeptides as selective somatostatin sst5 receptor agonists. 6 are defined herein, and the... |
|
|
Invention
|
Glp-1 receptor antagonists. 1, AA2, LysR, X and Y are defined herein, and their use in treating, ... |
|
2015
|
P/S
|
Proteins and proteins in the nature of G-protein-coupled receptors, for use in pharmaceutical res... |
|
2010
|
P/S
|
Chemicals and proteins used in industry and science;
chemical and proteins for drug discovery, l... |
